Table 1.

Distribution of miRNA expression in CD138+ plasma cells of patients with smoldering MM and MM, as well as in CD138+ plasma cells of MM patient subgroups.

Variable	Mean ± S.E. 1	Range	Percentiles
			25th	50th (Median)	75th
miR-16-5p levels (RQU 2)
in sMM patients	44.58 ± 14.04	0.004–167.3	2.94	10.16	82.20
in MM patients	13.77 ± 4.10	0.046–264.5	1.77	3.54	10.26
miR-155-5p levels (RQU 2)
in sMM patients	1285.7± 539.8	<0.001–6097.5	15.06	182.8	1402.7
in MM patients	366.0 ± 167.6	<0.001–9738.0	2.21	23.05	130.3
miR-15a-5p levels (RQU 2)
in MM patients without osteolytic lesions	29.93 ± 12.66	0.008–181.0	1.76	7.30	22,29
in MM patients with osteolytic lesions	7.71 ± 3.25	0.003–122.9	0.37	1.85	6.76
miR-16-5p levels (RQU 2)
in MM patients without osteolytic lesions	19.27 ± 7.18	0.92–109.9	3.07	7.06	15.68
in MM patients with osteolytic lesions	7.49 ± 2.39	0.12–82.77	1.39	2.64	8.50
miR-222-3p levels (RQU 2)
in MM patients without osteolytic lesions	10.95 ± 3.17	0.006–54.28	1.56	8.03	15.57
in MM patients with osteolytic lesions	6.03 ± 1.65	0.007–43.54	0.06	2.56	6.55
miR-125b-5p levels (RQU 2)
in MM patients without SREs 3	15.00 ± 8.12	0.001–139.8	0.17	1.17	15.62
in MM patients with SREs 3	39.39 ± 12.72	0.12–247.7	5.96	26.28	44.75

¹ Standard error. ² Relative quantification unit. ³ Skeletal-related events.